Basilea announced encouraging interim data from cohort 2 of the FIDES-01 Phase II trial in intrahepac cholangiocarcinoma ("iCCA") paents with FGFR mutaons amplificaons. The disease control rate ("DCR") of 79% is higher than that observed for paents with FGFR2 fusions in the first cohort (73%) and a prespecified criterion on 3-month progression free survival ("PFS") was met, enabling the progression of the study to the next stage. Although sll not fully mature, this data connues to suppo ....
25 Mar 2021
More evidence of derazantinib's potential in iCCA
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
More evidence of derazantinib's potential in iCCA
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
25 Mar 2021 -
Author:
KIERON BANERJEE -
Pages:
5
Basilea announced encouraging interim data from cohort 2 of the FIDES-01 Phase II trial in intrahepac cholangiocarcinoma ("iCCA") paents with FGFR mutaons amplificaons. The disease control rate ("DCR") of 79% is higher than that observed for paents with FGFR2 fusions in the first cohort (73%) and a prespecified criterion on 3-month progression free survival ("PFS") was met, enabling the progression of the study to the next stage. Although sll not fully mature, this data connues to suppo ....